- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01729351
Qvar Therapy in Smoking Asthmatics
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma - a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Aged 16-70 years
- Current smokers - explicitly coded in patient records or captured in patient questionnaires
- Evidence of asthma diagnosis and current therapy: ≥2 prescriptions for asthma at different points in time during the baseline year ± a diagnostic code for asthma
- On-going asthma therapy: ≥2 prescription for ICS during the outcome period (i.e. ≥1 prescription in addition to IPD prescription)
- ≥2 years continuous data (i.e. ≥1 year of baseline plus ≥1 year of outcome data)
Exclusion Criteria:
Patients will be excluded from the analysis if they have:
- Any chronic respiratory disease other than asthma
- Are prescribed:
- Maintenance oral steroid therapy during the baseline year
- Combination ICS/long-acting beta agonist (LABA) therapy during baseline year or at IPD
- Multiple ICS prescriptions at IPD or immediately before .
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
IPDI EF HFA-BDP
Pacientes que inician la terapia con corticosteroides inhalados como MDI HFA-BDP extrafino en la fecha índice
|
|
IPDI FP
Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
|
|
IPDI NEF HFA-BDP
Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
|
|
IPDA EF HFA-BDP
Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
|
|
IPDA FP
Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
|
|
IPDA NEF HFA-BDP
Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Asthma Control proxy incorporating SABA use
Periodo de tiempo: 1 year
|
Where control is defined as absence of: (i)Respiratory-related: Hospital attendance or admission A&E attendance, OR Out of hours attendance, OR Out-patient department attendance (ii)GP consultations for lower respiratory tract infection (iii)Prescriptions for acute courses of oral steroids (iv)Average prescribed daily dose of albuterol or terbutaline of ≤200mg |
1 year
|
|
Asthma Exacerbations (ATS Definition)
Periodo de tiempo: 1 year
|
Defined as an absence of the the following:
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Exacerbation definition based on clinical experience
Periodo de tiempo: 1 year
|
Defined as: (i)Respiratory-related: Hospital attendance / admissions OR A&E attendance OR Out of hours consultation OR GP consultation OR (ii) Use of acute oral steroids |
1 year
|
|
Asthma control proxy excluding SABA usage
Periodo de tiempo: 1 year
|
Control defined as absence of: (i) Respiratory-related: Hospital attendance or admission A&E attendance, OR Out of hours attendance, OR Out-patient department attendance (ii)GP consultations for lower respiratory tract infection (iii)Prescriptions for acute courses of oral steroids |
1 year
|
|
Treatment Success
Periodo de tiempo: 1 year
|
Success defined as: No respiratory-related: Hospital attendance or admission A&E attendance, OR Out of hours consultation, OR Out-patient department attendance No GP consultations for lower respiratory tract infection No prescriptions for acute courses of oral steroids No additional or change in therapy: Increased dose of ICS (≥50% increase), and/or Change in ICS and/or Change in delivery device, and/or Use of additional therapy as defined by: LABA, theophylline, leukotriene receptor antagonists (LTRAs). |
1 year
|
|
Definite asthma-related hospitalisations
Periodo de tiempo: 1 year
|
Hospitalisations coded with an asthma read code
|
1 year
|
|
ICS Compliance
Periodo de tiempo: 1 year
|
Based on prescription refills
|
1 year
|
|
Incidence of oral thrust
Periodo de tiempo: 1 year
|
Identified as:
|
1 year
|
|
SABA Dose
Periodo de tiempo: 1 year
|
Average daily dose of short-acting beta-agonist over the outcome year
|
1 year
|
|
Definite and probable asthma-related hospitalisations
Periodo de tiempo: 1 year
|
Hospitalisations with an asthma read code + uncoded hospitalisations occurring within a 7-day window (either side of the hospitalisation date) of an asthma read code
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: David Professor Price, University of Aberdeen
Publicaciones y enlaces útiles
Publicaciones Generales
- Price D, Martin RJ, Barnes N, Dorinsky P, Israel E, Roche N, Chisholm A, Hillyer EV, Kemp L, Lee AJ, von Ziegenweidt J, Colice G. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol. 2010 Sep;126(3):511-8.e1-10. doi: 10.1016/j.jaci.2010.06.040. Epub 2010 Aug 9.
- Barnes N, Price D, Colice G, Chisholm A, Dorinsky P, Hillyer EV, Burden A, Lee AJ, Martin RJ, Roche N, von Ziegenweidt J, Israel E. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy. 2011 Nov;41(11):1521-32. doi: 10.1111/j.1365-2222.2011.03820.x. Epub 2011 Jul 14.
- Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax. 1999 May;54(5):413-9. doi: 10.1136/thx.54.5.413.
- Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL. Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care. 2008 Dec;14(12):801-9.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- R01911
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .